检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:杨欣[1] 吴宜勇[2] 张绍芬[3] 樊继援[4] 耿力[5] 陈淑玲[1] 郑淑蓉[1]
机构地区:[1]北京大学第一医院妇产科,北京100034 [2]北京医院,北京100730 [3]复旦大学附属妇产医院,上海200011 [4]天津医科大学总医院,天津300052 [5]北京大学第三医院妇产科,北京100083
出 处:《中国临床药理学杂志》2008年第3期199-203,共5页The Chinese Journal of Clinical Pharmacology
摘 要:目的研究国产盐酸利塞膦酸钠(第3代双膦酸盐类抗骨吸收剂)对绝经后妇女骨密度(BMD)及骨代谢的影响。方法用多中心、随机、双盲安慰剂对照临床研究,240名绝经后妇女每天接受利塞膦酸钠5mg(n=120),或安慰剂(n=120),治疗12个月;每位受试者于服药前及服药12个月后,各进行1次BMD、血生化指标的测定,骨代谢标志物在用药前及用药后6个月测定。结果利塞膦酸钠组腰椎BMD百分数增加4.83%;而安慰剂组增加1.15%(P<0.001)。利塞膦酸钠髋部BMD增加3.52%;而安慰剂组增加1.84%(P<0.01)。利塞膦酸钠组骨代谢指标血清骨钙素上升23.1%;而安慰剂组上升37.1%(P<0.05),2组C-端交联肽分别降低72.7%和40.6%(P<0.001)。结论利塞膦酸钠能增加绝经后妇女骨密度并降低了骨吸收指标。Objective To determine the effect of risedronate on bone mineral density (BMD) , bone metabolism markers in Chinese postmenopausal women. Methods This was a multicenter, randomized, double blind placebo controlled study in China with a total of 240 postmenopausal women treated with either risedronate 5 mg (n = 120) or placebo (n = 120) daily for 12 months. BMD, bone markers were determined before and after drug administration. Results The percentage increase in total lumbar spine BMD was 4.83 % with risedronate compared to increase of 1.15% with placebo (P 〈 0.01 ). Corresponding values for total hip BMD were 3.52% increase for risedronate and 1.84% for placebo (P 〈 0.001 ) . For biochemical markers of bone metabolism, serum osteocalcin were 23.1% increase and C -telopeptide 72.7% decrease in risedronate -treated subjects, and corresponding values in placebo were 37.1% increase and 40.6% decrease ( risedronate compared to placebo, P 〈 0.05, P 〈 0. 001 ). Conclusion This study confirms that risedronate exerts positive effects on the skeleton, increasing BMD and decreasing absorptive biochemical markers of bone metabolism.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.56